Followers | 1076 |
Posts | 80420 |
Boards Moderated | 5 |
Alias Born | 03/10/2009 |
Wednesday, January 02, 2019 9:52:59 PM
The following table shows the amount of our common stock beneficially owned as of November 30, 2018 by (i) each person or group as those terms are used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), believed by us to beneficially own more than 5% of our common stock, (ii) each of our directors, (iii) each of our named executive officers, and (iv) all of our directors and named executive officers as a group. Except as otherwise noted, each person named in the table has sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.
Name of Beneficial Owner (1)
Number of
Shares of
Common Stock
Beneficially
Owned
(2)
Percentage of
Shares of
Common
Stock
Beneficially
Owned
(3)
Executive Officers and Directors
Myron Holubiak (4)
2,152,569
11.54
%
Leonard Mazur (5)
11,077,506
50.30
%
Jaime Bartushak (6)
113,027
*
Suren Dutia (7)
36,667
*
Dr. William Kane (8)
35,405
*
Howard Safir (8)
35,405
*
Carol Webb (8)
35,405
*
Eugene Holuka (9)
25,749
*
All executive officers and directors as a group (8 people)
13,511,730
58.52
%
Other 5% holders
Armistice Capital, LLC(10)
1,797,866
9.99
%
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 09:26:01 PM
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:15:10 PM
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology • PR Newswire (US) • 09/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:55 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/16/2024 08:34:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:25:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:19:43 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/12/2024 09:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:25:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/12/2024 09:10:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:51:13 PM
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. • PR Newswire (US) • 08/12/2024 08:22:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments • PR Newswire (US) • 08/12/2024 12:00:00 PM
- TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update • GlobeNewswire Inc. • 08/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:20:18 PM
- Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 08/08/2024 10:59:00 AM
- Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. • PR Newswire (US) • 08/05/2024 12:00:00 PM
- TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates • PR Newswire (US) • 07/10/2024 01:10:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution • PR Newswire (US) • 05/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:34 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM